Wilma van Bentum-Puijk

Intravenous Vitamin C for Patients Hospitalized With COVID-19

Simin Aysel Florescu, Dragos Stanciu, Mihaela Zaharia, Alma Kosa et autres

Importance: The efficacy of vitamin C for hospitalized patients with COVID-19 is uncertain. Objective: To determine whether vitamin C improves outcomes for patients with COVID-19. Design, Setting, and Participants: Two prospectively harmonized randomized clinical trials enrolled critically ill patients receiving organ support …

Continuation of therapeutic dose heparin for critically ill patients with COVID-19

Charlotte Bradbury, Patrick R. Lawler, Bryan J. McVerry, Ryan Zarychanski et autres

gb, ca, us (code pays fourni par la source)

Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support–Free Days in Patients Hospitalized With COVID-19

Simin Aysel Florescu, Dragos Stanciu, Mihaela Zaharia, Alma Kosa et autres

IMPORTANCE: Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective: To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS: …

Heterogeneous Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19

Ewan C. Goligher, Patrick R. Lawler, Thomas P. Jensen, Victor B. Talisa et autres

Importance: Randomized clinical trials (RCTs) of therapeutic-dose heparin in patients hospitalized with COVID-19 produced conflicting results, possibly due to heterogeneity of treatment effect (HTE) across individuals. Better understanding of HTE could facilitate individualized clinical decision-making. Objective: To evaluate HTE of therapeutic-dose heparin …

ca, us, gb, nz, au (code pays fourni par la source)

Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial

Simin Florescu, Delia Stanciu, Mihaela Zaharia, Alma Kosa et autres

Importance: The longer-term effects of therapies for the treatment of critically ill patients with COVID-19 are unknown. Objective: To determine the effect of multiple interventions for critically ill adults with COVID-19 on longer-term outcomes. Design, Setting, and Participants: Prespecified secondary analysis of …

Effect of Antiplatelet Therapy on Survival and Organ Support–Free Days in Critically Ill Patients With COVID-19

Simin Florescu, Delia Stanciu, Mihaela Zaharia, Alma Kosa et autres

Importance: The efficacy of antiplatelet therapy in critically ill patients with COVID-19 is uncertain. Objective: To determine whether antiplatelet therapy improves outcomes for critically ill adults with COVID-19. Design, Setting, and Participants: In an ongoing adaptive platform trial (REMAP-CAP) testing multiple interventions …

Effect of Convalescent Plasma on Organ Support–Free Days in Critically Ill Patients With COVID-19

Hesham Abdelhady, Marwa Abdelrazik, Zakee Abdi, David Abdo et autres

IMPORTANCE: The evidence for benefit of convalescent plasma for critically ill patients with COVID-19 is inconclusive. OBJECTIVE: To determine whether convalescent plasma would improve outcomes for critically ill adults with COVID-19. DESIGN, SETTING, AND PARTICIPANTS: The ongoing Randomized, Embedded, Multifactorial, Adaptive Platform …

Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial

Yaseen M. Arabi, Anthony Gordon, Lennie Derde, Alistair Nichol et autres

sa, gb, nl, ie, au, ca, fr, nz, us, de, be (code pays fourni par la source)

Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19

Isabel Mur, Gràcia Mateo, María del Mar Gutiérrez, Virginia Pomar et autres

Importance: Clinical trials assessing the efficacy of IL-6 antagonists in patients hospitalized for COVID-19 have variously reported benefit, no effect, and harm. Objective: To estimate the association between administration of IL-6 antagonists compared with usual care or placebo and 28-day all-cause mortality …

it, es, nl, gb, ca (code pays fourni par la source)

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 – Preliminary report

Anthony Gordon, Paul Mouncey, Farah Al-Beidh, Kathy Rowan et autres

Abstract Background The efficacy of interleukin-6 receptor antagonists in critically ill patients with coronavirus disease 2019 (Covid-19) is unclear. Methods We evaluated tocilizumab and sarilumab in an ongoing international, multifactorial, adaptive platform trial. Adult patients with Covid-19, within 24 hours of commencing …

gb, ie, au, sa, fr, nl, us, ca, de, nz, be, lk, th, fi (code pays fourni par la source)

Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19

Derek C. Angus, Lennie Derde, Farah Al-Beidh, Djillali Annane et autres

Importance: Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19) is limited. Objective: To determine whether hydrocortisone improves outcome for patients with severe COVID-19. Design, Setting, and Participants: An ongoing adaptive platform trial testing multiple interventions within multiple therapeutic domains, for …

us, nl, gb, fr, sa, ca, de, au, be, th, nz, ie (code pays fourni par la source)

The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and Design

Derek C. Angus, Scott Berry, Roger Lewis, Farah Al-Beidh et autres

Abstract There is broad interest in improved methods to generate robust evidence regarding best practice, especially in settings where patient conditions are heterogenous and require multiple concomitant therapies. Here, we present the rationale and design of a large, international trial that combines …

us, gb, sa, ca, de, au, fr, nl, be, nz, ie (code pays fourni par la source)